Neogenomics, Inc. share price today

(NEO)

Neogenomics, Inc. share price is $17.19 & ₹1,455.01 as on 6 Dec 2024, 2.30 'hrs' IST

$17.19

▲

-0.82

(-4.55%)

Market is closed - opens 8 PM, 06 Dec 2024

View live Neogenomics, Inc. share price in Dollar and Rupees. Guide to invest in Neogenomics, Inc. from India. Also see the sentimental analysis on Indian investors investing in Neogenomics, Inc.. Get details on the Indian mutual funds that are investing in Neogenomics, Inc.. Get Analyst recommendations and forecasts along with all the Neogenomics, Inc.'s financials.

Neogenomics, Inc. share price movements

$17.19
$17.98
$17.19
0.0%
Downside
Day's Volatility :4.39%
Upside
4.39%
$12.77
$21.22
$17.19
25.71%
Downside
52 Weeks Volatility :39.82%
Upside
18.99%

Neogenomics, Inc. Returns

Period	Neogenomics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	7.17%	-5.7%	0.0%
6 Months	32.13%	-0.8%	0.0%
1 Year	-4.18%	9.9%	0.0%
3 Years	-49.34%	10.7%	-19.7%

Neogenomics, Inc. Key Statistics

in dollars & INR

Previous Close	$18.01
Open	$17.93
Today's High	$17.98
Today's Low	$17.19
Market Capitalization	$2.3B
Today's Volume	$659.8K
52 Week High	$21.22
52 Week Low	$12.77
Revenue TTM	$644.1M
EBITDA	$-447.0K
Earnings Per Share (EPS)	$-0.61
Profit Margin	-12.07%
Quarterly Earnings Growth YOY	1.31%
Return On Equity TTM	-8.38%

How to invest in Neogenomics, Inc. from India?

It is very easy for Indian residents to invest directly in Neogenomics, Inc. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Neogenomics, Inc. stock in both rupees (INR) and dollars (USD). Search for Neogenomics, Inc. or NEO on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Neogenomics, Inc. or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Neogenomics, Inc. shares which would translate to 0.049 fractional shares of Neogenomics, Inc. as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Neogenomics, Inc.

-28%

Period: Sep 6, 2024 to Dec 5, 2024. Change in 30 Days versus previous period

Search volume for Neogenomics, Inc. on INDmoney from India has reduced in the last 30 days as on Dec 6, 2024. -28% less investors are searching Neogenomics, Inc. in the last 30 days versus the previous period.

Global Institutional Holdings in Neogenomics, Inc.

BlackRock Inc
15.32%
Vanguard Group Inc
10.94%
Brown Advisory Holdings Inc
5.37%
HHG PLC
5.14%
T. Rowe Price Investment Management,Inc.
5.10%
State Street Corp
3.86%

Analyst Recommendation on Neogenomics, Inc.

Buy

76%Buy

23%Hold

0%Sell

Based on 17 Wall street analysts offering stock ratings for Neogenomics, Inc.(by analysts ranked 0 to 5 stars)

Based on 17 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Neogenomics, Inc.

What analysts predicted

Upside of 21.64%

Current:

$17.19

Target:

$20.91

Insights on Neogenomics, Inc.

Increasing Revenue
Revenue is up for the last 7 quarters, 137.22M → 167.82M (in $), with an average increase of 3.3% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -27.06M → -17.69M (in $), with an average increase of 25.2% per quarter
Vs A
In the last 1 year, Agilent Technologies Inc. has given 7.0% return, outperforming this stock by 12.5%
Vs A
In the last 3 years, Neogenomics, Inc. has experienced a drawdown of -45.6%, however Agilent Technologies Inc. resisted the overall trend and outperformed by 36.6%

Neogenomics, Inc. Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$276.7M	↑ 7.01%
Net Income	$2.6M	↓ 412.06%
Net Profit Margin	0.95%	↑ 1.28%

	FY19	Y/Y Change
Revenue	$408.8M	↑ 47.73%
Net Income	$8.0M	↑ 203.26%
Net Profit Margin	1.96%	↑ 1.01%

	FY20	Y/Y Change
Revenue	$444.4M	↑ 8.71%
Net Income	$4.2M	↓ 47.89%
Net Profit Margin	0.94%	↓ 1.02%

	FY21	Y/Y Change
Revenue	$484.3M	↑ 8.97%
Net Income	$-8.3M	↓ 300.07%
Net Profit Margin	-1.72%	↓ 2.66%

	FY22	Y/Y Change
Revenue	$509.7M	↑ 5.24%
Net Income	$-144.3M	↑ 1628.17%
Net Profit Margin	-28.3%	↓ 26.58%

	FY23	Y/Y Change
Revenue	$591.6M	↑ 16.07%
Net Income	$-88.0M	↓ 39.02%
Net Profit Margin	-14.87%	↑ 13.43%

	Q2 FY23	Q/Q Change
Revenue	$146.9M	↑ 7.07%
Net Income	$-24.3M	↓ 20.99%
Net Profit Margin	-16.56%	↑ 5.88%

	Q3 FY23	Q/Q Change
Revenue	$152.0M	↑ 3.43%
Net Income	$-18.5M	↓ 23.9%
Net Profit Margin	-12.19%	↑ 4.37%

	Q4 FY23	Q/Q Change
Revenue	$155.6M	↑ 2.37%
Net Income	$-14.3M	↓ 22.63%
Net Profit Margin	-9.21%	↑ 2.98%

	Q1 FY24	Q/Q Change
Revenue	$156.2M	↑ 0.44%
Net Income	$-27.1M	↑ 88.89%
Net Profit Margin	-17.32%	↓ 8.11%

	Q2 FY24	Q/Q Change
Revenue	$164.5M	↑ 5.29%
Net Income	$-18.6M	↓ 31.11%
Net Profit Margin	-11.33%	↑ 5.99%

	Q3 FY24	Q/Q Change
Revenue	$167.8M	↑ 2.02%
Net Income	$-17.7M	↓ 5.06%
Net Profit Margin	-10.55%	↑ 0.78%

	FY18	Y/Y Change
Total Assets	$505.0M	↑ 47.09%
Total Liabilities	$184.6M	↑ 33.94%

	FY19	Y/Y Change
Total Assets	$709.5M	↑ 40.49%
Total Liabilities	$202.1M	↑ 9.5%

	FY20	Y/Y Change
Total Assets	$988.3M	↑ 39.3%
Total Liabilities	$294.0M	↑ 45.49%

	FY21	Y/Y Change
Total Assets	$1.9B	↑ 89.19%
Total Liabilities	$761.5M	↑ 158.98%

	FY22	Y/Y Change
Total Assets	$1.7B	↓ 6.94%
Total Liabilities	$742.0M	↓ 2.56%

	FY23	Y/Y Change
Total Assets	$1.7B	↓ 3.38%
Total Liabilities	$739.7M	↓ 0.31%

	Q2 FY23	Q/Q Change
Total Assets	$1.7B	↓ 0.82%
Total Liabilities	$738.9M	↑ 0.57%

	Q3 FY23	Q/Q Change
Total Assets	$1.7B	↓ 1.0%
Total Liabilities	$730.8M	↓ 1.1%

	Q4 FY23	Q/Q Change
Total Assets	$1.7B	↑ 0.18%
Total Liabilities	$739.7M	↑ 1.21%

	Q1 FY24	Q/Q Change
Total Assets	$1.6B	↓ 2.43%
Total Liabilities	$716.9M	↓ 3.08%

	Q2 FY24	Q/Q Change
Total Assets	$1.6B	↑ 0.18%
Total Liabilities	$727.4M	↑ 1.46%

	Q3 FY24	Q/Q Change
Total Assets	$1.6B	↓ 0.13%
Total Liabilities	$732.9M	↑ 0.76%

	FY18	Y/Y Change
Operating Cash Flow	$44.8M	↑ 148.3%
Investing Cash Flow	$-139.7M	↑ 920.36%
Financing Cash Flow	$92.0M	↓ 2345.64%

	FY19	Y/Y Change
Operating Cash Flow	$23.4M	↓ 47.82%
Investing Cash Flow	$-19.6M	↓ 85.95%
Financing Cash Flow	$159.5M	↑ 73.41%

	FY20	Y/Y Change
Operating Cash Flow	$1.5M	↓ 93.75%
Investing Cash Flow	$-159.4M	↑ 712.23%
Financing Cash Flow	$235.6M	↑ 47.74%

	FY21	Y/Y Change
Operating Cash Flow	$-26.7M	↓ 1930.34%
Investing Cash Flow	$-632.4M	↑ 296.62%
Financing Cash Flow	$725.3M	↑ 207.85%

	FY22	Y/Y Change
Operating Cash Flow	$-66.0M	↑ 146.95%
Investing Cash Flow	$517.0K	↓ 100.08%
Financing Cash Flow	$11.8M	↓ 98.37%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-1.5M	↓ 87.8%
Investing Cash Flow	$14.9M	↓ 37.04%
Financing Cash Flow	$64.0K	↓ 95.36%

Neogenomics, Inc. Technicals Summary

Sell

Neutral

Buy

Neogenomics, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Neogenomics, Inc. Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Neogenomics, Inc.	11.19%	32.13%	-4.18%	-49.34%	-33.81%
Idexx Laboratories, Inc.	0.96%	-14.07%	-18.27%	-30.08%	71.67%
Agilent Technologies Inc.	0.07%	3.68%	7.14%	-10.36%	68.92%
Thermo Fisher Scientific, Inc.	-6.94%	-10.37%	5.42%	-17.15%	64.61%
Danaher Corp.	-8.03%	-13.38%	4.09%	-27.28%	54.46%
Iqvia Holdings Inc.	-9.64%	-8.8%	-7.0%	-26.03%	36.56%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Neogenomics, Inc.	NA	NA	3.02	0.1	-0.08	-0.03	NA	7.09
Idexx Laboratories, Inc.	41.3	41.3	4.5	10.73	0.59	0.23	NA	19.72
Agilent Technologies Inc.	31.62	31.62	2.38	5.24	0.25	0.08	0.01	20.53
Thermo Fisher Scientific, Inc.	32.68	32.68	1.99	21.69	0.13	0.05	0.0	128.08
Danaher Corp.	42.91	42.91	3.04	7.5	0.08	0.04	0.0	71.03
Iqvia Holdings Inc.	26.66	26.66	1.05	11.12	0.22	0.05	NA	38.37

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Neogenomics, Inc.	Buy	$2.3B	-33.81%	NA	-12.07%
Idexx Laboratories, Inc.	Buy	$35.0B	71.67%	41.3	22.53%
Agilent Technologies Inc.	Buy	$40.0B	68.92%	31.62	21.75%
Thermo Fisher Scientific, Inc.	Buy	$199.2B	64.61%	32.68	14.48%
Danaher Corp.	Buy	$164.6B	54.46%	42.91	16.39%
Iqvia Holdings Inc.	Buy	$36.9B	36.56%	26.66	9.17%

Neogenomics, Inc. Dividend announcements

Neogenomics, Inc. Earnings
Neogenomics, Inc.’s price-to-earnings ratio stands at None
Read More

About Neogenomics, Inc.

neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig

Organization	Neogenomics, Inc.
Employees	2100
CEO	Mr. Christopher Michael Smith BSc
Industry	Health Services

Management People of Neogenomics, Inc.

Name	Title
Mr. Christopher Michael Smith BSc	CEO & Director
Mr. Jeffrey S. Sherman M.B.A.	Chief Financial Officer
Mr. Vishal Sikri	President of Advanced Diagnostics
Ms. Melody Harris Esq., J.D.	President & COO of Informatics
Mr. Warren Stone	Chief Commercial Officer
Mr. Gregory D. Aunan	Chief Accounting Officer
Ms. Kendra Sweeney	Vice President of Investor Relations & Communications
Ms. Alicia Olivo	Executive VP of Business Development, General Counsel & Corporate Secretary
Mr. Hutan Hashemi J.D.	Chief Compliance Officer
Dr. Derek Lyle M.D.	Chief Medical Officer

Important FAQs about investing in Neogenomics, Inc. from India :

What is Neogenomics, Inc. share price today?

Neogenomics, Inc. (NEO) share price today is $17.19.

Can Indians buy Neogenomics, Inc. shares?

Yes, Indians can invest in the Neogenomics, Inc. (NEO) from India.

With INDmoney, you can buy Neogenomics, Inc. at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Neogenomics, Inc. at zero transaction cost.

How can I buy Neogenomics, Inc. shares from India?

It is very easy to buy Neogenomics, Inc. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Neogenomics, Inc. be purchased?

Yes, you can buy fractional shares of Neogenomics, Inc. with INDmoney app.

What are the documents required to start investing in Neogenomics, Inc. stocks?

To start investing in Neogenomics, Inc., You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.